Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.

Marzola MC, Chondrogiannis S, Grassetto G, Rampin L, Maffione AM, Ferretti A, Opocher G, Schiavi F, Colletti PM, Rubello D.

Clin Nucl Med. 2014 Jan;39(1):e53-8. doi: 10.1097/RLU.0b013e31829aface.

PMID:
23856824
2.

Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.

Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, Galli G, Fanti S, Giordano A.

Nucl Med Commun. 2011 Jul;32(7):575-82. doi: 10.1097/MNM.0b013e328345a340.

PMID:
21471850
3.

Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.

Rischke HC, Benz MR, Wild D, Mix M, Dumont RA, Campbell D, Seufert J, Wiech T, Rössler J, Weber WA, Neumann HP.

J Nucl Med. 2012 Sep;53(9):1352-8. doi: 10.2967/jnumed.111.101303. Epub 2012 Jul 26.

4.

6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP.

J Clin Endocrinol Metab. 2009 Oct;94(10):3922-30. doi: 10.1210/jc.2009-1054. Epub 2009 Jul 21.

PMID:
19622618
5.

Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K.

J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28.

6.

18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.

Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW.

J Nucl Med. 2009 Apr;50(4):513-9. doi: 10.2967/jnumed.108.058396. Epub 2009 Mar 16.

7.

Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.

Havekes B, van der Klaauw AA, Weiss MM, Jansen JC, van der Mey AG, Vriends AH, Bonsing BA, Romijn JA, Corssmit EP.

Endocr Relat Cancer. 2009 Jun;16(2):527-36. doi: 10.1677/ERC-09-0024. Epub 2009 Mar 16.

8.

(18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.

Magnaldi S, Mayerhoefer ME, Khameneh A, Schuetz M, Javor D, Mitterhauser M, Dudczak R, Hacker M, Karanikas G.

Anticancer Res. 2014 Feb;34(2):791-5.

PMID:
24511014
9.

Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas.

Bacca A, Chiacchio S, Zampa V, Carrara D, Duce V, Congregati C, Simi P, Taddei S, Materazzi G, Volterrani D, Mariani G, Bernini G.

Clin Nucl Med. 2014 Jan;39(1):14-20. doi: 10.1097/RLU.0000000000000242.

PMID:
24300347
10.

A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1800-8. doi: 10.1007/s00259-013-2548-y. Epub 2013 Sep 27.

PMID:
24072345
11.

The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.

Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams KT, Pacak K.

J Nucl Med. 2007 Oct;48(10):1599-606. Epub 2007 Sep 14.

12.

A family with pheochromocytoma-paraganglioma inherited tumour syndrome. Serial 18F-DOPA PET/CT investigations.

Knie B, Plotkin M, Zschieschang P, Prasad V, Moskopp D.

Nuklearmedizin. 2016;55(1):34-40. doi: 10.3413/Nukmed-0755-15-07. Epub 2016 Jan 7.

PMID:
26740102
13.

Familial pheochromocytoma.

Erlic Z, Neumann HP.

Hormones (Athens). 2009 Jan-Mar;8(1):29-38.

14.

Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.

Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Reynolds JC, Ling A, Eisenhofer G, Lazúrová I, Adams KT, Whatley MA, Widimsky J Jr, Pacak K.

Endocr Relat Cancer. 2008 Mar;15(1):311-23. doi: 10.1677/ERC-07-0217.

15.

Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?

Hentschel M, Rottenburger C, Boedeker CC, Neumann HP, Brink I.

Clin Nucl Med. 2012 Feb;37(2):e24-9. doi: 10.1097/RLU.0b013e318238f550.

PMID:
22228360
16.

Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, Ling A, Adams KT, Xekouki P, Lando H, Stratakis CA, Pacak K.

J Clin Endocrinol Metab. 2011 Sep;96(9):2779-85. doi: 10.1210/jc.2011-0333. Epub 2011 Jul 13.

17.

Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.

Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG.

J Clin Endocrinol Metab. 2006 Mar;91(3):827-36. Epub 2005 Nov 29.

PMID:
16317055
18.

Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.

Srirangalingam U, Walker L, Khoo B, MacDonald F, Gardner D, Wilkin TJ, Skelly RH, George E, Spooner D, Monson JP, Grossman AB, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL.

Clin Endocrinol (Oxf). 2008 Oct;69(4):587-96. doi: 10.1111/j.1365-2265.2008.03274.x. Epub 2008 Apr 14.

PMID:
18419787
19.

18F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L.

Feral CC, Tissot FS, Tosello L, Fakhry N, Sebag F, Pacak K, Taïeb D.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):812-821. doi: 10.1007/s00259-016-3586-z. Epub 2016 Nov 29.

PMID:
27900521
20.

Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K.

J Natl Cancer Inst. 2012 May 2;104(9):700-8. doi: 10.1093/jnci/djs188. Epub 2012 Apr 18.

Supplemental Content

Support Center